CNSP News and Press, CNS Pharmaceuticals Inc. From 07/01/21

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Among the highlights, the company reported on its continued prog...

CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM Recently launched potentially pivotal study for lead program evaluating Berubicin in the treatment of adult Glioblastom...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the U.S. Food and Drug Administration granted Fast Track Designation for Berubicin,...

Palm Beach, FL – June 29, 2021 – Cancer is a foremost public health problem globally and is the second leading cause of death in the United States.  According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and app...

Palm Beach, FL – June 29, 2021 – Glioblastoma multiforme (GBM) is one of the areas where the research & development investments are high and where global studies are growing. Everyone is looking to solve the problem. GBM, a fast-growing and aggressive brain tumor, is a dev...

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme - FDA Fast Track Designation for Berubicin highlights the serious unmet medical need for new treatments for glioblastoma multiforme (GBM) - Company r...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, sublicenses the compound Berubicin to WPD Pharmaceuticals for 30 countries mainly in Europe and As...

WPD Pharmaceuticals (WPDPF) announces that it plans to commence a phase Ib/II study of berubicin for the treatment of glioblastoma ((GBM)) in the second half of this year.CNS Pharmaceuticals (CNSP), the company that sublicenses the compound to WPD for 30 countries mainly in Europe&#...

VANCOUVER, British Columbia, June 28, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company ” or “ WPD ”) a clinical-stage pharmaceutical company, today provided an update on its Berubicin drug candidate clinical deve...

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead drug candidate, Berubicin, is a novel anthracycline, the first of which to appear capable of crossing the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin in the treatment of several serious br...